JP6401772B2 - ヘモグロビンの修飾のための化合物及びその使用 - Google Patents
ヘモグロビンの修飾のための化合物及びその使用 Download PDFInfo
- Publication number
- JP6401772B2 JP6401772B2 JP2016501086A JP2016501086A JP6401772B2 JP 6401772 B2 JP6401772 B2 JP 6401772B2 JP 2016501086 A JP2016501086 A JP 2016501086A JP 2016501086 A JP2016501086 A JP 2016501086A JP 6401772 B2 JP6401772 B2 JP 6401772B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- ring
- mmol
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC*C(CC(C(C)C)C(C)C1C(*C(C)CC(C2)C22CC(CC3)C3C2)C1)*C Chemical compound CC*C(CC(C(C)C)C(C)C1C(*C(C)CC(C2)C22CC(CC3)C3C2)C1)*C 0.000 description 21
- ZKZJXVGTTZXHGX-UHFFFAOYSA-N CC(C)[n]1nccc1B1OC(C)(C)C(C)(C)O1 Chemical compound CC(C)[n]1nccc1B1OC(C)(C)C(C)(C)O1 ZKZJXVGTTZXHGX-UHFFFAOYSA-N 0.000 description 1
- AHYUYTPSMFBALO-UHFFFAOYSA-N CC(C)[n]1nccc1C(C1)=C(CO)CCN1C(C)=O Chemical compound CC(C)[n]1nccc1C(C1)=C(CO)CCN1C(C)=O AHYUYTPSMFBALO-UHFFFAOYSA-N 0.000 description 1
- XMBBQPHHBFAYJM-RYJYUDELSA-N CC(C)[n]1nccc1C(CNC1)C1NC(C(/C(/C=O)=C(\C=C/C)/O)=C)=O Chemical compound CC(C)[n]1nccc1C(CNC1)C1NC(C(/C(/C=O)=C(\C=C/C)/O)=C)=O XMBBQPHHBFAYJM-RYJYUDELSA-N 0.000 description 1
- SDZYZUXRBWFEGJ-UHFFFAOYSA-N CC(C)[n]1nccc1C1=C(COc2c(C=O)c(C)ccc2)CCS(C)C1 Chemical compound CC(C)[n]1nccc1C1=C(COc2c(C=O)c(C)ccc2)CCS(C)C1 SDZYZUXRBWFEGJ-UHFFFAOYSA-N 0.000 description 1
- FPNFCRQOIYNGAC-UHFFFAOYSA-N CC(C)[n]1nccc1C1=C(COc2c(C=O)c(O)ccc2)CSCC1 Chemical compound CC(C)[n]1nccc1C1=C(COc2c(C=O)c(O)ccc2)CSCC1 FPNFCRQOIYNGAC-UHFFFAOYSA-N 0.000 description 1
- FMPAANGPHXVCIN-UHFFFAOYSA-N CC(C)[n]1nccc1C1=C(COc2cccc(O)c2C=O)CN(C)C1 Chemical compound CC(C)[n]1nccc1C1=C(COc2cccc(O)c2C=O)CN(C)C1 FMPAANGPHXVCIN-UHFFFAOYSA-N 0.000 description 1
- ZZCXLMMGLYKSAA-UHFFFAOYSA-N CC(C)[n]1nccc1C1C(COc2c(C=O)c(O)ccc2)C(C)SC1 Chemical compound CC(C)[n]1nccc1C1C(COc2c(C=O)c(O)ccc2)C(C)SC1 ZZCXLMMGLYKSAA-UHFFFAOYSA-N 0.000 description 1
- KDGZYCLKPOHFBQ-UHFFFAOYSA-N CC(C)[n]1nccc1C1C(COc2c(C=O)c(O)ccc2)COC1 Chemical compound CC(C)[n]1nccc1C1C(COc2c(C=O)c(O)ccc2)COC1 KDGZYCLKPOHFBQ-UHFFFAOYSA-N 0.000 description 1
- HMNXVZQOXWPPLV-UHFFFAOYSA-N CC(C)[n]1nccc1C1N(COc2c(C=O)c(C)ccc2)CCC1 Chemical compound CC(C)[n]1nccc1C1N(COc2c(C=O)c(C)ccc2)CCC1 HMNXVZQOXWPPLV-UHFFFAOYSA-N 0.000 description 1
- ZABUPVJRHBRIJF-UHFFFAOYSA-N CC(C)[n]1nccc1N1C(COc2c(C=O)c(O)ccc2)CSCC1 Chemical compound CC(C)[n]1nccc1N1C(COc2c(C=O)c(O)ccc2)CSCC1 ZABUPVJRHBRIJF-UHFFFAOYSA-N 0.000 description 1
- CDURSEAMBZODLJ-UHFFFAOYSA-N CCOC(C(CC=[O]C1)C1=O)=O Chemical compound CCOC(C(CC=[O]C1)C1=O)=O CDURSEAMBZODLJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/815,776 | 2013-03-15 | ||
| US13/815,776 US9458139B2 (en) | 2013-03-15 | 2013-03-15 | Compounds and uses thereof for the modulation of hemoglobin |
| US201361905802P | 2013-11-18 | 2013-11-18 | |
| US61/905,802 | 2013-11-18 | ||
| PCT/US2014/022846 WO2014150289A1 (en) | 2013-03-15 | 2014-03-10 | Compounds and uses thereof for the modulation of hemoglobin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018167981A Division JP2018188481A (ja) | 2013-03-15 | 2018-09-07 | ヘモグロビンの修飾のための化合物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512824A JP2016512824A (ja) | 2016-05-09 |
| JP2016512824A5 JP2016512824A5 (enExample) | 2017-04-13 |
| JP6401772B2 true JP6401772B2 (ja) | 2018-10-10 |
Family
ID=51580734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501086A Expired - Fee Related JP6401772B2 (ja) | 2013-03-15 | 2014-03-10 | ヘモグロビンの修飾のための化合物及びその使用 |
| JP2018167981A Pending JP2018188481A (ja) | 2013-03-15 | 2018-09-07 | ヘモグロビンの修飾のための化合物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018167981A Pending JP2018188481A (ja) | 2013-03-15 | 2018-09-07 | ヘモグロビンの修飾のための化合物及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2970315B1 (enExample) |
| JP (2) | JP6401772B2 (enExample) |
| KR (1) | KR20150132147A (enExample) |
| CN (1) | CN105209469A (enExample) |
| AP (1) | AP2015008720A0 (enExample) |
| AU (1) | AU2014237361A1 (enExample) |
| BR (1) | BR112015021980A2 (enExample) |
| CA (1) | CA2902721C (enExample) |
| EA (1) | EA201591427A1 (enExample) |
| ES (1) | ES2909634T3 (enExample) |
| IL (1) | IL240845A0 (enExample) |
| MX (1) | MX388013B (enExample) |
| PE (1) | PE20151907A1 (enExample) |
| SG (1) | SG11201507351PA (enExample) |
| TW (1) | TW201518286A (enExample) |
| UY (1) | UY35425A (enExample) |
| WO (1) | WO2014150289A1 (enExample) |
| ZA (1) | ZA201506390B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| PL2797416T3 (pl) | 2011-12-28 | 2017-12-29 | Global Blood Therapeutics, Inc. | Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek |
| EP2968299B1 (en) | 2013-03-15 | 2021-01-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN116270646A (zh) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| PL3383392T3 (pl) | 2015-12-04 | 2025-11-17 | Global Blood Therapeutics, Inc. | Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| WO2017218960A1 (en) | 2016-06-17 | 2017-12-21 | Fronthera U.S. Pharmaceuticals Llc | Hemoglobin modifier compounds and uses thereof |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| PT3880654T (pt) * | 2018-11-19 | 2022-04-08 | Global Blood Therapeutics Inc | Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina |
| SG11202104585YA (en) | 2018-11-29 | 2021-06-29 | Pfizer | Pyrazoles as modulators of hemoglobin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL64573A (en) * | 1980-12-18 | 1985-04-30 | Wellcome Found | Derivatives of formylphenoxyalkanoic acids and formylphenoxymethylbenzoic acids,their preparation and pharmaceutical formulations containing them |
| FR2680512B1 (fr) * | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| HU224548B1 (hu) * | 1993-04-07 | 2005-10-28 | Taiho Pharmaceutical Co. Ltd. | Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra |
| JP2000514041A (ja) * | 1996-07-26 | 2000-10-24 | ドクター・レディーズ・リサーチ・ファウンデーション | 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物 |
| US6184228B1 (en) * | 1999-05-25 | 2001-02-06 | Anadys Pharmaceuticals, Inc. | Anti-sickling agents: selection methods and effective compounds |
| AUPQ105499A0 (en) * | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
| US20030022923A1 (en) * | 2001-03-01 | 2003-01-30 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| ATE527238T1 (de) * | 2002-12-04 | 2011-10-15 | Univ Virginia Commonwealth | Mittel mit wirkung gegen sichelzellenanämie |
| BRPI0417186A (pt) * | 2003-12-02 | 2007-03-06 | Celgene Corp | método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica |
| DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| US20120122928A1 (en) * | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
| PL2797416T3 (pl) * | 2011-12-28 | 2017-12-29 | Global Blood Therapeutics, Inc. | Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek |
| BR112015021982B1 (pt) * | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
-
2014
- 2014-03-10 PE PE2015001920A patent/PE20151907A1/es not_active Application Discontinuation
- 2014-03-10 EP EP14768414.6A patent/EP2970315B1/en active Active
- 2014-03-10 EA EA201591427A patent/EA201591427A1/ru unknown
- 2014-03-10 CN CN201480013378.3A patent/CN105209469A/zh active Pending
- 2014-03-10 WO PCT/US2014/022846 patent/WO2014150289A1/en not_active Ceased
- 2014-03-10 SG SG11201507351PA patent/SG11201507351PA/en unknown
- 2014-03-10 JP JP2016501086A patent/JP6401772B2/ja not_active Expired - Fee Related
- 2014-03-10 AP AP2015008720A patent/AP2015008720A0/xx unknown
- 2014-03-10 ES ES14768414T patent/ES2909634T3/es active Active
- 2014-03-10 BR BR112015021980A patent/BR112015021980A2/pt not_active IP Right Cessation
- 2014-03-10 AU AU2014237361A patent/AU2014237361A1/en not_active Abandoned
- 2014-03-10 CA CA2902721A patent/CA2902721C/en active Active
- 2014-03-10 MX MX2015011509A patent/MX388013B/es unknown
- 2014-03-10 KR KR1020157024775A patent/KR20150132147A/ko not_active Withdrawn
- 2014-03-13 TW TW103108889A patent/TW201518286A/zh unknown
- 2014-03-13 UY UY35425A patent/UY35425A/es not_active Application Discontinuation
-
2015
- 2015-08-26 IL IL240845A patent/IL240845A0/en unknown
- 2015-09-01 ZA ZA2015/06390A patent/ZA201506390B/en unknown
-
2018
- 2018-09-07 JP JP2018167981A patent/JP2018188481A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105209469A (zh) | 2015-12-30 |
| EA201591427A1 (ru) | 2016-01-29 |
| AU2014237361A1 (en) | 2015-09-17 |
| WO2014150289A1 (en) | 2014-09-25 |
| BR112015021980A2 (pt) | 2017-07-18 |
| CA2902721C (en) | 2021-09-14 |
| EP2970315A4 (en) | 2016-08-17 |
| IL240845A0 (en) | 2015-10-29 |
| CA2902721A1 (en) | 2014-09-25 |
| JP2016512824A (ja) | 2016-05-09 |
| JP2018188481A (ja) | 2018-11-29 |
| AP2015008720A0 (en) | 2015-09-30 |
| TW201518286A (zh) | 2015-05-16 |
| PE20151907A1 (es) | 2016-01-20 |
| MX388013B (es) | 2025-03-19 |
| ZA201506390B (en) | 2017-03-29 |
| MX2015011509A (es) | 2016-05-31 |
| KR20150132147A (ko) | 2015-11-25 |
| EP2970315B1 (en) | 2021-09-15 |
| EP2970315A1 (en) | 2016-01-20 |
| UY35425A (es) | 2014-10-31 |
| SG11201507351PA (en) | 2015-10-29 |
| ES2909634T3 (es) | 2022-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018188481A (ja) | ヘモグロビンの修飾のための化合物及びその使用 | |
| JP6690861B2 (ja) | ヘモグロビンの修飾のための化合物及びその使用 | |
| JP6401771B2 (ja) | ヘモグロビンの修飾のための化合物及びその使用 | |
| US10100040B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| US10450269B1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| JP6463327B2 (ja) | ヘモグロビンの修飾のための化合物及びその使用 | |
| OA17478A (en) | Compounds and uses thereof for the modulation of hemoglobin. | |
| OA17480A (en) | Compounds and uses thereof for the modulation of hemoglobin. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170309 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170309 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180313 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180613 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180710 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180808 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180907 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6401772 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |